BioArctic AB 2017 AR2
The report highlights BioArctic's successful listing on Nasdaq Stockholm in October 2017, marking the largest biotech IPO in Sweden since 2000. The company continued to advance its clinical projects, including the Phase 2b study of BAN2401 for Alzheimer's disease and the Phase 1/2 study of SC0806 for complete spinal cord injury. BioArctic expanded its strategic collaborations with global partners Eisai and AbbVie, securing significant funding. Financially, net sales increased to MSEK 140.7, driven by the Parkinson's disease research collaboration with AbbVie.
Company: BioArctic AB
Sector: Professional & technical services
Country: Sweden
Year: 2017
Type: AR2
Pages: 92
Back to company
BioArctic AB
Annual Report
The report highlights BioArctic's successful listing on Nasdaq Stockholm in October 2017, marking the largest biotech IPO in Sweden since 2000. The company continued to advance its clinical projects, including the Phase 2b study of BAN2401 for Alzheimer's disease and the Phase 1/2 study of SC0806 for complete spinal cord injury. BioArctic expanded its strategic collaborations with global partners Eisai and AbbVie, securing significant funding. Financially, net sales increased to MSEK 140.7, driven by the Parkinson's disease research collaboration with AbbVie.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees